Program
SHR-9539
A development code. Also written as “SHR-9539 for injection”.
Its studies are mostly in Multiple Myeloma, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 11 open or running | phase 1since Jun 26, 2024 | Jun 26, 2024 | Jul 31, 2027phase 1 · NCT06484777 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-9539
, phase 1, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2024First study: phase 1 study in Multiple MyelomaFirst studyNCT06484777 · 138 planned · China
Ahead
- Jul 31, 2027Primary completion: phase 1 study in Multiple MyelomaNCT06484777
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06484777Multiple Myeloma · China | 1 | Recruiting | Jul 31, 2027 | 138 |
How it is read
Names in the registry
- “SHR-9539 for injection”, 1 entry
Codes read as this program: SHR9539.
Conditions, from the studies’ own filings
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.